NCT07216482
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 35 versions: 34 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
- Trial completed
- Study completion date changed from estimate of Nov 5, 2026 to Oct 27, 2026
- Secondary endpoints: details revised at 2 of 9 entries
- Site details revised at 4 of 87 sites
- Minor Enrollment target: estimated 975 to confirmed 996
- Study sites: 89 to 87
- Primary completion date changed from estimate of Aug 12, 2026 to Aug 3, 2026
- Minor Primary completion moved earlier from Dec 2, 2026 to Aug 12, 2026
- Study completion moved earlier from Mar 1, 2027 to Nov 5, 2026
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Site details revised at 89 of 89 sites
- Minor Site details revised at 4 of 89 sitesv31
Show 28 earlier versionsHide 28 earlier versions
- Minor Site details revised at 11 of 89 sitesv30
- Minor Site details revised at 2 of 89 sitesv29
- Minor Site details revised at 38 of 89 sitesv28
- Minor Site details revised at 24 of 89 sitesv27
- Minor Site details revised at 4 of 89 sitesv26
- Minor Study sites: 88 to 89v25
- Minor Study sites revised (88)v24
- Minor Site details revised at 1 of 88 sitesv23
- Minor Study sites revised (88)v22
- Minor Study sites: 87 to 88v21
- Minor Study sites: 82 to 87v20
- Minor Study sites: 81 to 82v19
- Minor Study sites: 80 to 81v18
- Minor Study sites: 78 to 80v17
- Minor Study sites: 77 to 78v15
- Minor Study sites: 72 to 77v14
- Minor Study sites: 63 to 72v13
- Minor Study sites: 61 to 63v12
- Minor Study sites: 59 to 61v11
- Minor Study sites: 56 to 59v10
- Minor Study sites: 55 to 56v9
- Minor Study sites: 53 to 55v8
- Minor Study sites: 47 to 53v7
- Minor Study sites: 44 to 47v6
- Minor Study sites: 42 to 44v5
- Minor Study sites: 37 to 42v4
- Minor Study sites: 30 to 37v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 30
- Start date changed from estimate of Nov 19, 2025 to Nov 11, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants will receive enlicitide and a rosuvastatin-matching placebo. Both will be delivered orally once daily (QD) for up to 12 weeks.
Participants will receive enlicitide and rosuvastatin. Both will be delivered orally QD for up to 12 weeks.
Participants will receive rosuvastatin and an enlicitide-matching placebo. Both will be delivered orally QD for up to 12 weeks.
Participants will receive an enlicitide-matching placebo and a rosuvastatin-matching placebo. Placebos will be delivered orally QD for up to 12 weeks.
Drugs: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin
Sites
87 sites in 11 countries
United States 35, Argentina 7, Australia 6, Canada 6, Turkey (Türkiye) 6, Brazil 5, Israel 5, New Zealand 5, United Kingdom 5, Hungary 4, Spain 3